GE HealthCare has dosed the first patient in a Phase 2/3 trial of a manganese-based MRI contrast agent and secured FDA clearance for three next-generation SIGNA MRI systems. The contrast agent aims to ...
New MRI technology aims to advance neuroimaging and biomarker research CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results